Long-Term Evolocumab Safe and Effective for Treating Hypercholesterolemia

Evolocumab consistently reduced LDL-C with no increase in adverse events over a 5-year study period.

Source link

Related posts

JACC Instructions for Authors


Translating the Translation: What Clinicians Should Know About the Fourth Universal Definition of Myocardial Infarction


Maternal Exposure to Ambient Particulate Matter


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy